Roche: US Biosimilar Impact Worse Than Expected And ‘Pretty Much Like Europe’
Avastin EU Biosimilars Marked Complete Level Of Competition
Roche was forced to revise its forecasts for biosimilar competition last year, but even an upward revision of CHF1bn fell short as biosimilar sponsors stole a march in the US at a level that caught the originator by surprise.
